B.C. Reg. 135/2019: Amendments to the Drug Schedules Regulation
Made under the Pharmacy Operations and Drug Scheduling Act
How does this rule affect your organization? One Click reads it against your profile and tells you, on Canada Federal Legislative Tracking. See plans →
Get alerted when the next rule lands
New rules land on their own schedule. Pick how you want to hear about them — we email you when one appears.
Publishing to members? Embed a live rule tracker on your own site — the proposed rules in your area and the comment deadlines closing on them, updating themselves. Free, one line of HTML.
The rule, in full
315 words as published, June 18, 2019. View the original →
B.C. Reg. 135/2019, deposited June 17, 2019, under the PHARMACY OPERATIONS AND DRUG SCHEDULING ACT [section 22 (1)]. Resolution of the Board of the College of Pharmacists of British Columbia, dated April 11, 2019. Resolution of the Board of the College of Pharmacists of British Columbia made the 11th date of April, 2019 RESOLVED THAT, in accordance with the authority established in section 22 (1) of the Pharmacy Operations and Drug Scheduling Act, and subject to filing with the Minister as required by section 22 (2) of the Pharmacy Operations and Drug Scheduling Act, the board amend the Drug Schedules Regulation, B.C. Reg. 9/98, to move esomeprazole when sold for treatment of frequent heartburn from Schedule II to Schedule III and establish esomeprazole for veterinary use as Schedule I. — B. NAKAGAWA, Registrar.
Appendix
1 The Drug Schedules Regulation, B.C. Reg. 9/98, is amended in the Schedules (a) by striking out the following: 1 Esomeprazole and its salts except when sold for the 14-day treatment for frequent heartburn, at a daily dose of 20 mg and in package sizes of no more than 280 mg of esomeprazole 2 Esomeprazole and its salts when sold for the 14-day treatment for frequent heartburn, at a daily dose of 20 mg and in package sizes of no more than 280 mg of esomeprazole , and (b) by adding the following: 1 Esomeprazole or its salts for human use including but not limited to esomeprazole magnesium except when sold for the 14-day treatment for frequent heartburn at a daily dose of 20 mg, in package sizes of no more than 280 mg of esomeprazole 3 Esomeprazole or its salts for human use when sold for the 14-day treatment for frequent heartburn at a daily dose of 20 mg, in package sizes of no more than 280 mg of esomeprazole 1 Esomeprazole or its salts for veterinary use .
Documents
- The text in The British Columbia Gazette · June 18, 2019